The point of care diagnostics market is entering a steady growth phase, driven by an aging global population, rising chronic and infectious disease burden, and the ongoing shift toward decentralized, rapid-result testing. Here's a breakdown of where the market stands today and where it's headed through 2033.

Key Market Metrics & Projections

• Market size: $21.7 billion in 2025
• Estimated to reach $22.6 billion in 2026
• Projected to grow to $29.9 billion by 2033
• Growth rate: 4.1% CAGR (2026–2033)
• North America led in 2025 with a 37.1% revenue share, backed by high healthcare spending, a large geriatric population, and strong EMR/PACS penetration
• Asia Pacific is the fastest-growing region, with a projected CAGR of roughly 6.3% through the forecast period

Market Segmentation & Domain Leadership

By Product: The infectious diseases segment dominates, capturing about 30.5% of global revenue in 2025. Demand here is being driven by faster, more accessible rapid-testing platforms — from molecular PCR tests that deliver results in minutes to decentralized testing kits reaching underserved regions. Meanwhile, the cancer markers segment is set to grow fastest, as rising global cancer incidence pushes demand for early, in-clinic detection tools.

By End Use: Clinics hold the largest share, as primary care settings increasingly shift from sending samples to central labs toward on-site testing — cutting turnaround time and cost. The home care segment is the fastest-growing end-use category, driven by patient preference for convenience, an aging population managing chronic conditions, and the broader push to reduce hospital readmissions.

Curious what's inside the full report?
Download a Free Sample and explore the complete market data, trends, and forecasts firsthand.

Core Growth Drivers & Disruptions

Several forces are shaping the market's next phase of growth:

• Aging population: The number of people aged 65+ is climbing rapidly worldwide, and this group is disproportionately affected by diabetes, cardiovascular disease, and cancer — all conditions well-suited to POC monitoring.
• Rising chronic and infectious disease prevalence: Diabetes cases alone are projected to grow from roughly 537 million globally in 2021 to over 780 million by 2045, while infectious diseases continue to drive demand for rapid diagnostic turnaround.
• Government and institutional funding: Public health bodies continue to back diagnostic innovation — recent examples include funding awarded to validate new biomarker technologies for pediatric conditions.
• Product innovation: Companies are continuously rolling out next-generation devices, from portable RT-PCR machines to new coagulation testing platforms for anticoagulant management.
• M&A and strategic partnerships: The industry sees a high volume of consolidation activity as larger players acquire specialized diagnostics firms to expand technology portfolios and global reach.
• Regulatory tailwinds: Accelerated approval pathways for infectious disease diagnostics and CLIA-waiver programs are expanding where and how POC tests can be used — including pharmacies and home settings.

Key Industry Players

The competitive landscape is anchored by a mix of established multinational diagnostics leaders and specialized players, including:

• F. Hoffmann-La Roche Ltd.
• Abbott
• Danaher Corporation
• Siemens Healthcare GmbH
• Becton Dickinson (BD)
• bioMérieux
• Qiagen
• Werfen
• QuidelOrtho Corporation
• Nova Biomedical
• OraSure Technologies, Inc.
• EKF Diagnostics Holdings plc.

Established players are investing heavily in R&D and forming partnerships with emerging innovators, while smaller companies focus on targeted regional launches before scaling. Recent moves include Siemens Healthineers' $150 million U.S. manufacturing expansion, QuidelOrtho's acquisition of LEX Diagnostics to strengthen its molecular diagnostics pipeline, and BD's plan to separate its Biosciences and Diagnostic Solutions businesses to sharpen strategic focus.

Want deeper insight into a specific segment, region, or competitor? Customize This Report — get up to 20% free customization tailored to your exact research needs.